Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Scilex Holding Co's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $-192.64 Mil. Scilex Holding Co's Total Assets for the quarter that ended in Dec. 2024 was $92.95 Mil.
Therefore, Scilex Holding Co's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was -2.07.
The historical rank and industry rank for Scilex Holding Co's Equity-to-Asset or its related term are showing as below:
SCLX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -2.87 Med: -1.74 Max: 0.42
Current: -2.07
During the past 6 years, the highest Equity to Asset Ratio of Scilex Holding Co was 0.42. The lowest was -2.87. And the median was -1.74.
SCLX's Equity-to-Asset is ranked worse than 96.68% of 1025
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs SCLX: -2.07
Scilex Holding Co Equity-to-Asset Historical Data
The historical data trend for Scilex Holding Co's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Scilex Holding Co's Equity-to-Asset
For the Drug Manufacturers - General subindustry, Scilex Holding Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scilex Holding Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Scilex Holding Co's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Scilex Holding Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scilex Holding Co (NAS:SCLX) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Scilex Holding Co Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Scilex Holding Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCLX has been successfully added to your 